Professor Kenji Osafune (Department of Cell Growth and Differentiation) and his team of researchers have devised an effective means to grow iPS cell-derived kidney progenitor cells, paving the way for renal regenerative therapies to become a reality. The findings are published in the journal Science Translational Medicine.
Modern medicine continues to be hampered by the lack of effective treatments for acute kidney injury (AKI) and chronic kidney disease (CKD). Regenerative medicine, such as cell replacement therapies, represents a new hope for patients. Yet, such therapeutic approaches require large-scale production of the necessary cells, which had remained a challenge until this discovery.
Using a mouse model of AKI, the research team first demonstrated the therapeutic potential of human iPS cell-derived nephron progenitor cells (hiPSC-NPCs). When these cells were transplanted into the kidneys of AKI mouse models induced by an anti-cancer drug, cisplatin, the animals’ survival was vastly improved by preventing the deterioration of kidney function.